Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ch14.18/CHO Continuous Infusion in Relapsed/Refractory Neuroblastoma
NCT02743429Phase 2Unknown
- Sponsor
- Universitätsklinikum Greifswald
- Start
- Mar 2015
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of Dinutuximab beta in neuroblastoma, sponsored by Universitätsklinikum Greifswald. Status: unknown.
02
Drugs
Dinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02743429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743429.